pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CRISPR/Cas9 · news · pharmadog
← back to CRISPR/Cas9
News · CRISPR/Cas9
130
stories
1d
Epicrispr builds case for FSHD treatment with updated data for EPI-321
endpoints
3d
Foghorn cuts 40% of workforce
biospace
4d
Mistrust in science and a juicy gene-editing lawsuit
stat
5d
STAT+: Pharmalittle: We’re reading about Beam suing over IP theft, a Trump rule on importing meds, and more
stat
6d
Beam Therapeutics sues base editing rival, claims former scientist stole secrets
fiercebiotech
6d
Beam sues YolTech and Serapha Bio for allegedly stealing its gene editing tech
endpoints
6d
Beam sues 2 biotechs, alleging theft of base editing trade secrets
biopharma dive
6d
Researchers slow neurodegeneration in mice by barring T cells from the brain
stat
7d
Trump uses ‘contested’ power to cut more funding to HHS
stat
10d
Endpoints 11 2026 winner Azalea melds gene editing and CAR-T
endpoints
13d
ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands
biospace
21d
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
fiercebiotech
21d
Blood centers can help biopharma scale cell and gene therapies
biospace
21d
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
biopharma dive
22d
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
fiercebiotech
22d
After a brief storm of political headwinds, mRNA is back with strong momentum
biospace
25d
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
25d
A booming business on Wall Street would love more biotechs to quietly die
biopharma dive
27d
Moonwalk reloads with $70M and new RNAi prospects for obesity
biopharma dive
27d
Moonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinic
biospace
28d
Diabetes cell therapy biotechs Sernova and Seraxis to merge
endpoints
Sep 4, 26
10 life sciences startups selected for accelerator program
biospace
Sep 3, 26
US to grant up to $125M for personalized RNA manufacturing innovation
biospace
Sep 2, 26
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
biopharma dive
Sep 2, 26
China deaths reignite debate about using viruses to deliver CRISPR therapies
endpoints
Sep 2, 26
Typewriter raises $56M for jumping gene technology and in vivo CAR-T therapies
endpoints
Sep 1, 26
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
biospace
Aug 28, 26
#ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy
endpoints
Aug 27, 26
CAR Ts will only treat autoimmune diseases if we can scale delivery
biospace
Aug 26, 26
An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies
endpoints
← prev
page 1 of 5
next →
